FDA permits initiation of GlycoDesign's phase I/II study of GD0039 as chemoprotective agent Feb. 22, 1999 No Comments
Licensing partner sought for development of prohibitin gene-based cancer Rx, Dx Feb. 22, 1999 No Comments
Protein farnesyltransferase inhibitors in development at Bristol-Myers Squibb Feb. 19, 1999 No Comments
Genzyme's oncology division in-licenses angiogenesis inhibitor for development Feb. 19, 1999 No Comments
RSS